Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
详细信息 查看全文
- 作者：Andrea Messori (1)
Valeria Fadda (1)
Dario Maratea (1)
Sabrina Trippoli (1)
Claudio Marinai (1) - 关键词：Dipeptidylpeptidase ; 4 inhibitors ; DPP ; 4 ; Equivalence ; Meta ; analysis ; Type 2 diabetes
- 刊名：Diabetes Therapy
- 出版年：2014
- 出版时间：June 2014
- 年：2014
- 卷：5
- 期：1
- 页码：341-344
- 全文大小：371 KB
- 参考文献：1. Messori A, Fadda V, Gatto R, Maratea D, Trippoli S. Differentiating between “no proof of difference-and “proof of no difference-for new oral anticoagulants. BMJ. 2014;6(348):g1955. doi:10.1136/bmj.g1955 . CrossRef
2. Messori A, Fadda V, Maratea D, Trippoli S. Rates of inhibitor development in previously untreated patients with severe hemophilia a treated with plasma-derived or recombinant Factor VIII: no proof of difference or proof of no difference? Semin Thromb Hemost. 2014;40(2):269-0. CrossRef
3. Messori A, Fadda V, Maratea D, Trippoli S. Erythropoietin in patients with acute myocardial infarction: no proof of effectiveness or proof of no effectiveness? Clin Cardiol. 2013;36(10):E39-0.
4. Craddy P, Palin HJ, Johnson KI. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther. 2014 (Epub ahead of print).
5. Ahn S, Park SH, Lee KH. How to demonstrate similarity by using noninferiority and equivalence statistical testing in radiology research. Radiology. 2013;267(2):328-8. CrossRef
6. Christensen E. Methodology of superiority vs. equivalence trials and non-inferiority trials. J Hepatol. 2007;46(5):947-4. CrossRef
7. Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, Hoogwerf BJ, Gao A, Boardman MK, Fineman M, Porter L, Schernthaner G. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-4. CrossRef - 作者单位：Andrea Messori (1)
Valeria Fadda (1)
Dario Maratea (1)
Sabrina Trippoli (1)
Claudio Marinai (1)
1. HTA Unit, ESTAV Toscana Centro, Regional Health Service, 50100, Florence, Italy - ISSN：1869-6961
文摘
Background In studying the therapeutic evidence of innovative drug treatments, increasing attention is being devoted to differentiating between results that indicate no significant differences among the treatments under examination (“no proof of difference- and results that demonstrate the therapeutic equivalence among the treatments (“proof of no difference-. Aim Our analysis was aimed at evaluating the degree of therapeutic equivalence for dipeptidylpeptidase-4 (DPP-4) inhibitors given in type 2 diabetes as monotherapy or in combination with metformin. Methods Equivalence was determined by developing a standard Forest plot that incorporated the information on margins previously reported in randomized trials on these agents. The end point was HbA1c change from baseline; the equivalence margin was set at ±0.25% change in HbA1c. The clinical material was obtained from a systematic review on this topic. Results Given as monotherapy, linagliptin, sitagliptin, and vildagliptin (but not saxagliptin) met the equivalence criterion when compared with one another. Given in combination with metformin, linagliptin, saxagliptin, sitagliptin, and vildagliptin showed an equivalent effect whereas alogliptin did not satisfy the equivalence criterion. Conclusions Considering the most recent therapeutic guidelines, our results are of interest particularly as regards the information on DPP-4 inhibitors in combination with metformin. Four of the five DPP-4 inhibitors under examination clearly showed to have the same effectiveness; the fifth agent—alogliptin—failed to meet the equivalence criterion, but only because its superiority could not be excluded.